A 76‑year‑old Japanese‑American woman with a decade of advanced Alzheimer’s disease showed dramatic, short‑term gains after a single 5‑gram dose of psilocybin‑rich Enigma mushrooms. Eighty‑five hours later, she spoke autobiographically, restored urinary continence, walked independently, and engaged socially.

The case follows a second 3‑gram session a month later, after initial benefits persisted. Clinicians noted no lasting agitation, cardiovascular instability, or psychosis. The improvements spanned speech, mobility, dressing, and emotional reciprocity—domains usually lost in late‑stage dementia.

Researchers highlight the report as evidence that residual neural networks may be transiently re‑engaged by serotonergic psychedelics, thanks to 5‑HT2A receptor‑mediated plasticity. The findings do not claim disease reversal but suggest that neuromodulation can unlock dormant function.

These observations prompt a re‑examination of late‑stage Alzheimer’s care, implying that high‑dose psilocybin could become a targeted intervention for restoring autonomy when traditional therapies fail.